Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alcheme Bio Inc. operates within the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This specific matter is assigned to 1 distinct examiner, CHOWDHURY, IQBAL HOSSAIN. As the only examiner currently reviewing a case for the company, CHOWDHURY, IQBAL HOSSAIN is also the busiest examiner with 1 pending office action.
The portfolio is active in 1 distinct art unit. Because there is only a single pending office action, the distinct examiner and distinct art unit represent the entire current workload at the USPTO. This concentration means that the company's interactions are limited to a single administrative division and one individual's review process. Practitioners can focus their strategy on the specific tendencies of the art unit and the assigned examiner.
The 1 pending office action in the Biotechnology & Pharmaceuticals area defines the company's current administrative footprint. With the distinct examiner and the art unit, the prosecution is highly centralized. This allows for a specific analysis of the examiner's history and the art unit's standards. The company is not currently managing multiple simultaneous matters across different areas of the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.6% | +57.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19319578 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF CELLULAR AGRICULTURE PROTEIN PRODUCTS | CHOWDHURY, IQBAL HOSSAIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19319578 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF CELLULAR AGRICULTURE PROTEIN PRODUCTS | CHOWDHURY, IQBAL HOSSAIN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19319578 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF CELLULAR AGRICULTURE PROTEIN PRODUCTS | CHOWDHURY, IQBAL HOSSAIN | 1656 | §102§103§112 | Final Rejection | — | Pending | Sep 04, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlcheme Bio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Iqbal Hossain Chowdhury has the most, with 1 of Alcheme Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
